Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CellaVision AB ( (SE:CEVI) ) has provided an update.
CellaVision’s Q2 2025 report shows a robust performance with a 7.6% organic sales growth despite mixed regional results. The APAC region saw significant growth due to increased shipments to China, while the Americas and EMEA experienced moderate growth. The company is advancing strategic priorities, including clinical trials for bone marrow analysis and software upgrades, and maintains a strong financial position. The departure of CFO Magnus Blixt marks a significant leadership change.
More about CellaVision AB
CellaVision AB operates in the healthcare sector, focusing on digital cell morphology solutions. The company provides innovative diagnostic tools that enhance laboratory workflows, particularly in hematology, with a strong market presence in regions like APAC, Americas, and EMEA.
Average Trading Volume: 20,368
Current Market Cap: SEK4.31B
Learn more about CEVI stock on TipRanks’ Stock Analysis page.